スポンサーサイト

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。


Cancer Topics Index 04/29/2016(Daily Test version/ 日刊テスト版)No.20

konpas.jpg
Cancer Topics Index 04/29/2016(Daily Test version/ 日刊テスト版) No.20

Flags 【海外:overseas】
logo-clinicaltrials-gov.png
rinnsyo1.jpg
※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
16 studies found for: cancer | received from 04/15/2016 to 04/15/2016

【乳がん】
1 Not yet recruiting
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
Condition: Breast Cancer
Interventions: Other: ptDNA; Other: Tissue sample
Sponsor:Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:NCT02743910

【乳がん】
2 Not yet recruiting
Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer
Conditions: Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4); Stage IIb Breast Cancer (T3N0)
Intervention: Other: Whole-body FDG PET-CT alone
Sponsor:Ontario Clinical Oncology Group (OCOG)
ClinicalTrials.gov Identifier:NCT02751710

【前立腺がん】
3 Recruiting
Targeted Fusion Biopsy of the Prostate
Condition: Prostatic Neoplasms
Interventions: Drug: FACBC PET-CT Scan; Procedure: Three-dimensional ultrasound-guided biopsy; Procedure: Standard transrectal ultrasound (TRUS) guided biopsy
Sponsor:Emory University
ClinicalTrials.gov Identifier:NCT02744534

【膵がん】
4 Not yet recruiting
Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Radiation: Re-irradiation with SBRT
Sponsor:Changhai Hospital
ClinicalTrials.gov Identifier:NCT02745847

【下顎腫瘍】
5 Not yet recruiting
Inferior Alveolar Nerve Block for Intraoperative Analgesia for Maxillofacial Cancer Surgery - RCT
Condition: Mandibular Neoplasms
Intervention: Procedure: inferior alveolar nerve block
Sponsor:Tata Memorial Centre
ClinicalTrials.gov Identifier:NCT02745288

【前立腺がん】
6 Recruiting
Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.
Condition: Prostate Cancer
Intervention: Radiation: radiotherapy
Sponsor:University Hospital, Ghent
ClinicalTrials.gov Identifier:NCT02745587

【リンパ腫】
7 Not yet recruiting
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma
Conditions: B-Cell, Malignancy; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphocytic, Chronic, B-Cell
Interventions: Drug: JNJ-64052781; Drug: Ibrutinib
Sponsor:Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:NCT02743546

【がん】
8 Not yet recruiting
Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer
Condition: Advanced Cancer
Interventions: Drug: Nivolumab; Other: Placebo
Sponsor:Bristol-Myers Squibb
ClinicalTrials.gov Identifier:NCT02743494

【口腔扁平上皮がん】
9 Recruiting
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
Condition: Carcinoma, Squamous Cell
Interventions: Procedure: Resection for primary lesion and cervical lymph node dissection; Procedure: Resection for primary lesion
Sponsor:Jinsong Hou
ClinicalTrials.gov Identifier:NCT02743832

【肺がん】
10 Not yet recruiting
Phase 4 Field Study for Analyzing the Psychometric Properties of the EORTC Quality of Life Questionnaire (QLQ) LC29
Condition: Lung Cancer
Interventions: Other: Surgery; Other: Radiochemotherapy; Other: Targeted therapy
Sponsor:University Hospital Regensburg
ClinicalTrials.gov Identifier:NCT02745691

【子宮内膜がん】
11 Not yet recruiting
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
Condition: Endometrial Cancer
Intervention: Drug: Carboplatin AUC and Abraxane 100mg/m2
Sponsor:New York University School of Medicine
ClinicalTrials.gov Identifier:NCT02744898

【オピオイド誘発性便秘】
13 Not yet recruiting
Naloxegol in Cancer Opioid-Induced Constipation
Condition: Constipation
Intervention: Drug: naloxegol
Sponsor:University of California, San Diego
ClinicalTrials.gov Identifier:NCT02745353

【非ホジキンリンパ腫】
14 Not yet recruiting
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin's
Interventions: Drug: Obinutuzumab; Drug: Gemcitabine; Drug: Dexamethasone; Drug: Cisplatin
Sponsor:University Health Network, Toronto
ClinicalTrials.gov Identifier:NCT02750670

【肝細胞がん】
15 Not yet recruiting
HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China
Condition: Hepatocellular Carcinoma
Intervention: Device: HepaSphere with 50-75mg Doxorubicin
Sponsor:Fifth Affiliated Hospital, Sun Yat-Sen University
ClinicalTrials.gov Identifier:NCT02743065

<Medical Journal & Other News>
headline.jpg
【多発性骨髄腫/TJP1によりプロテアソーム阻害剤の有効性を識別】JOURNAL:Cancer Cell
TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors (04/28/2016 EurekAlert!/UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER)
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center.Multiple myeloma is a cancer that forms from white blood cells found in the bone marrow, normally vital to producing antibodies and maintaining a healthy immune system. It is the second most common type of blood cancer.

【抗血管新生療法の新たなアプローチ】JOURNAL:Cell Reports
A new discovery in the fight against cancer: Tumor cells switch to a different mode (04/28/2016 EurekAlert!/UNIVERSITY OF BASEL)
When medication is used to shut off the oxygen supply to tumor cells, the cells adapt their metabolism in the medium term -- by switching over to producing energy without oxygen. This observation by biomedical scientists at the University of Basel and University Hospital Basel could be used for treatments that can inhibit tumor growth in the long term, as the researchers report in the latest issue of the journal Cell Reports.

image1.jpg
【PM2.5が香港のがん死亡リスク増とリンク】JOURNAL:Cancer Epidemiology, Biomarkers & Prevention
Exposure to particulate air pollutants associated with numerous types of cancer (04/29/2016 EurekAlert!/AMERICAN ASSOCIATION FOR CANCER RESEARCH)
In 2015, the International Agency for Research on Cancer (IARC) published a series of monographs on the evaluation of various carcinogenic risks. In a monograph on air pollution, the organization pointed out the difficulty of assessing the effects of pollution on multiple types of cancers, given their different etiologies, risk factors and variability in the composition of air pollutants in space and time. However, the IARC identified certain key components of air pollution, including particulates.

Graphics 【日本国内:Japan】
<News>
自然に治る悪性腫瘍 いわゆるがんもどきはあるが全く医療を行わないは間違い (04/28/2016 BLOGOS)

<新刊メタデータ:New Books>
book_sepia.jpg
【タイトル】がんは人生を二度生きられる
著者:長尾 和宏/単行本(ソフトカバー): 192ページ/出版社: 青春出版社 (2016/4/29)/ISBN-10: 4413111680/ISBN-13: 978-4413111683/¥1,080

【タイトル】末期がん逆転の治療法
著者:前山 和宏/単行本(ソフトカバー): 228ページ/出版社: 幻冬舎メディアコンサルティング (2016/4/29)/ISBN-10: 4344974697/ISBN-13: 978-4344974692/¥1,404

【タイトル】ガンと闘わない治し方:ガンになっても『安心できる』13の実話
著者:森嶌 淳友/単行本(ソフトカバー): 208ページ/出版社: ヒカルランド (2016/4/27)/ISBN-10: 4864713707/ISBN-13: 978-4864713702/¥1,750

<雑誌記事:Magazine/Medical journal>
Stockholm Public Library
◆脳神経外科速報 (2016年5月号)/メディカ出版/発売日:2016年4月29日/価格(税込):2,700円
【タイトル】特集 グリオーマの基本と最新知識 ―脳腫瘍分類WHO updateを控えて
【Feature】グリオーマの基本と最新知識 ―脳腫瘍分類WHO updateを控えて
 広島大学病院 杉山一彦

<Special Interview>
・米国で活躍する日本人脳腫瘍外科医の挑戦 ―道標がないからおもしろい
 アラバマ大学バーミングハム校 中野伊知郎(聞き手:広島大学病院 杉山一彦)

<グリオーマ診療の基本を知る(1)>
・新しいグリオーマの分類 ―WHO updateについて
 兵庫県立がんセンター/神戸大学 廣瀬隆則

<グリオーマ診療の基本を知る(2)>
・グリオーマの画像診断
 広島大学 山崎文之 他

<グリオーマ診療の基本を知る(3)>
・テント上グリオーマの手術
 福島県立医科大学 藤井正純

<グリオーマ診療の基本を知る(4)>
・神経膠芽腫の放射線治療
 長崎大学病院 氏福健太 他

<グリオーマ診療の基本を知る(5)>
・グリオーマの化学療法
 慶應義塾大学 佐々木 光

<グリオーマ診療の基本を知る(6)>
・Tumor Treating Fieldsを用いた膠芽腫の治療
苫小牧市立病院 金子貞洋 他
関連記事


コメント
コメントの投稿


管理者にだけ表示を許可する

トラックバック
http://paxxmedia.blog38.fc2.com/tb.php/9100-4795faeb
この記事にトラックバックする(FC2ブログユーザー)


上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。